It takes several years of hard work to become an overnight success. Or so they say.

Everything around the breast cancer biotech drug trastuzumab smacks of this. After 19 years on the market, it is still one of the top-selling drugs for Roche, adding more than $30 billion in sales in just last five years. It will earn handsome revenues for Biocon in about a year from now. The final door to that market opened on 1 December when the Food and Drug Administration approved Biocon and its marketing partner Mylan’s Ogivri, trastuzumab biosimilar to Roche’s drug, for sale in the US market.

With this, Mylan-Biocon will become the first company to sell copies of this drug which has annual sales of $2 billion in the US. Worldwide, the drug, which Roche sells under the brand Herceptin, has three times bigger opportunity at the current price. It sells for $70,000 for a course in the US and is highly effective against a common breast cancer (where HER-2 gene is overexpressed) and metastatic stomach cancer.

It’s fair to say that the FDA approval is a big deal for Biocon-Mylan because snapping at their heels are drug giants like Amgen-Allergan, Pfizer, Samsung Bioepis and Celltrion developing biosimilars of trastuzumab and preparing to launch. Once the patent expires in 2019 in the US, only after which biosimilars could be sold, discounting will kick in. The trend shows it’s to the tune of 25-30%. And yet, there’s a huge market left and that explains why a complex patent dance ensues after every biotech drug goes off patent.

In this context, Mylan’s decision earlier in the year to secure global licenses for its trastuzumab product from Roche paves a clear pathway to commercialise Ogivri in various markets globally. “It is not clear if any of the other trastuzumab [biosimilar] developers have secured such a deal with Roche,” says a beaming Kiran Mazumdar-Shaw, chairperson and managing director of Biocon. The FDA stamp on biosimilars manufactured in India is a solid endorsement of quality when, today, Indian products, manufacturing plants and pharma data are all under heightened scrutiny of drug regulators worldwide.

Ring-fencing is the order of the (biologics’) day

The financial details of Mylan’s patent settlement with Roche have not been disclosed yet, but it sure looks like a masterstroke given how aggressively the innovator is guarding its turf as it gets closer to the patent cliff.

Roche’s strategy can be summed up in three words: Innovate. Protect. Expand. Innovate it does; just three of its products earned nearly $21 billion in 2016. Then it fiercely protects its innovation. In late November, it sued Pfizer for its proposed biosimilar of trastuzumab which “would infringe 40 patents”, it said in its complaint. Roche also wants compensation for lost sales if Pfizer launches its product before Herceptin patents expire, and some will start to in 2019.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.